A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

Researchers at UC San Francisco have now developed a way to reprogram these cancer-fighting cells directly inside the body. This new method could remove the need for external manufacturing, ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells — which have lost their cancer-fighting oomph — consume this lactic acid ...

SAN FRANCISCO -- The response rate in metastatic gastroesophageal cancer improved by a relative 50% when patients received experimental activated T cells in addition to standard therapy, according to ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...